Mirati's Sitravatinib Shows Promising Phase II Results in Urothelial Cancer Patients

Multi-targeted tyrosine kinase inhibitor sitravatinib was capable of producing a clinical benefit when combined with nivolumab in the majority of patients with checkpoint inhibitor-naïve, platinum-refractory urothelial cancer, according to Phase II trial data presented by Dr. Pavlos Msaouel, M.D., Ph.D., at the European Society for Medical Oncology Virtual Congress (ESMO) 2020. San Diego-based Mirati Therapeutics, a clinical-stage biotechnology company, is currently developing sitravatinib to address unmet medical needs in cancer care.